New to the market: Trinity Biotech facility

Trinity Biotech lab and manufacturing unit guiding at €10.5m

Sale of Nasdaq-listed company’s Bray facility offers purchaser net initial yield of 6.8%

Trinity Biotech

With more and more private and institutional investors targeting the Life Sciences sector since the unwelcome arrival of the Covid-19 pandemic, the sale of Trinity Biotech’s R&D laboratory and manufacturing facility at its headquarters in Bray, Co Wicklow, is expected to see strong interest.

The property, which is being offered to the market by agent Knight Frank at a guide price of €10.5 million, offers the prospective buyer a net initial yield of 6.8 per cent (assuming standard 9.96 per cent acquisition costs). The figure does not account for any benefit that might be accrued from the € 4.3 million capital allowance attached to the asset.

Located at the heart of the IDA Business Park on Bray’s Southern Cross Road, Block 2 is a modern two-storey high-tech laboratory production facility extending to 3,977sq m (42,817sq ft) with surface car-parking spaces and a secure service yard to warehouse/cold storage section.

Read the full article on the Irish Times website

Contact Ross Fogarty in our investment team for more information